These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 9466087)

  • 1. A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis.
    Perez EA
    Drug Saf; 1998 Jan; 18(1):43-56. PubMed ID: 9466087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis.
    Perez EA
    J Clin Oncol; 1995 Apr; 13(4):1036-43. PubMed ID: 7707101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
    Plosker GL; Benfield P
    Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stratified administration of serotonin 5-HT3 receptor antagonists (setrons) for chemotherapy-induced emesis. Economic implications.
    Sanchez LA; Holdsworth M; Bartel SB
    Pharmacoeconomics; 2000 Dec; 18(6):533-56. PubMed ID: 11227393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of experience with ondansetron and granisetron.
    Aapro MS
    Ann Oncol; 1993; 4 Suppl 3():9-14. PubMed ID: 8395875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study.
    Jantunen IT; Muhonen TT; Kataja VV; Flander MK; Teerenhovi L
    Eur J Cancer; 1993; 29A(12):1669-72. PubMed ID: 8398291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery.
    Balfour JA; Goa KL
    Drugs; 1997 Aug; 54(2):273-98. PubMed ID: 9257083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of oral 5-HT3 receptor antagonists for emetogenic chemotherapy.
    Anastasia PJ
    Oncol Nurs Forum; 2000 Apr; 27(3):483-93. PubMed ID: 10785902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-HT3 antiemetic therapy for patients with breast cancer.
    Perez EA
    Breast Cancer Res Treat; 1999 Sep; 57(2):207-14. PubMed ID: 10598048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting.
    Hesketh PJ
    Cancer Invest; 2000; 18(2):163-73. PubMed ID: 10705879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting.
    Simpson K; Spencer CM; McClellan KJ
    Drugs; 2000 Jun; 59(6):1297-315. PubMed ID: 10882164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost.
    Abali H; Celik I
    Cancer Invest; 2007; 25(3):135-9. PubMed ID: 17530482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in use of the 5-HT3 receptor antagonists.
    Walton SM
    Expert Opin Pharmacother; 2000 Jan; 1(2):207-23. PubMed ID: 11249543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy.
    Yarker YE; McTavish D
    Drugs; 1994 Nov; 48(5):761-93. PubMed ID: 7530631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
    Massidda B; Ionta MT
    J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-HT3 receptor antagonists: differences and similarities.
    Roila F; Ballatori E; Tonato M; Del Favero A
    Eur J Cancer; 1997 Aug; 33(9):1364-70. PubMed ID: 9337675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis.
    Jordan K; Hinke A; Grothey A; Voigt W; Arnold D; Wolf HH; Schmoll HJ
    Support Care Cancer; 2007 Sep; 15(9):1023-33. PubMed ID: 17205281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: a randomized study.
    Yalçin S; Tekuzman G; Baltali E; Ozişik Y; Barişta I
    Am J Clin Oncol; 1999 Feb; 22(1):94-6. PubMed ID: 10025391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.